Literature DB >> 15194583

Pharmaceutical treatment of symptomatic vertebral fractures in primary care.

D J Torgerson1, D Sykes, S Puffer, P Brown, C Cooper.   

Abstract

BACKGROUND: Vertebral fractures are associated with a reduction in quality of life and are an important predictor of other non-spine fractures. Previous work has shown that up to 60% of patients with a vertebral fracture identified in primary care remain untreated.
OBJECTIVE: To examine the prevalence of pharmaceutical treatment and predictors of treatment in a primary care setting.
METHODS: Case-control study using the general practice research database (GPRD). All women aged 50 years and over with a first diagnosis of a vertebral fracture since 1990 were identified and matched with a control by age and practice. Appropriate use of a pharmaceutical agent was defined as a prescription occurring within 30 days of the diagnosis being recorded.
RESULTS: We identified 2719 women with the same number of controls. Within 30 days of diagnosis 61% of women were prescribed treatment, compared with only 3% of the controls. Bisphosphonate was the single most important treatment prescribed. Predictors of any drug treatment included: year of fracture (most recent year increased the likelihood of treatment); age (younger patients were more likely to receive treatment); history of back pain; low body weight; history of steroid use.
CONCLUSIONS: Treatment of diagnosed vertebral fractures is becoming more common. Treated patients tend to be younger but to have a higher prevalence of clinical risk factors than untreated patients. There remain significant numbers of patients who are not offered treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15194583      PMCID: PMC1755056          DOI: 10.1136/ard.2003.013508

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  11 in total

1.  The UK General Practice Research Database.

Authors:  T Walley; A Mantgani
Journal:  Lancet       Date:  1997-10-11       Impact factor: 79.321

2.  Questionnaire survey of advice given to patients with fractures.

Authors:  B Pal
Journal:  BMJ       Date:  1999-02-20

3.  Unusual and memorable. Calcifying aponeurotic fibromata.

Authors:  I McCurdie; S S Jawad
Journal:  Ann Rheum Dis       Date:  1998-02       Impact factor: 19.103

4.  Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989.

Authors:  C Cooper; E J Atkinson; W M O'Fallon; L J Melton
Journal:  J Bone Miner Res       Date:  1992-02       Impact factor: 6.741

5.  Vertebral deformities as predictors of non-vertebral fractures.

Authors:  H Burger; P L van Daele; D Algra; A Hofman; D E Grobbee; H E Schütte; J C Birkenhäger; H A Pols
Journal:  BMJ       Date:  1994-10-15

6.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

7.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Authors:  M R McClung; P Geusens; P D Miller; H Zippel; W G Bensen; C Roux; S Adami; I Fogelman; T Diamond; R Eastell; P J Meunier; J Y Reginster
Journal:  N Engl J Med       Date:  2001-02-01       Impact factor: 91.245

8.  The cost utility of bisphosphonate treatment in established osteoporosis.

Authors:  C P Iglesias; D J Torgerson; A Bearne; U Bose
Journal:  QJM       Date:  2002-05

9.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

10.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors:  D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

View more
  2 in total

1.  Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study.

Authors:  T Armingeat; R Brondino; T Pham; V Legré; P Lafforgue
Journal:  Osteoporos Int       Date:  2006-08-08       Impact factor: 4.507

2.  Reporting of vertebral fractures on spine X-rays.

Authors:  J Fechtenbaum; C Cropet; S Kolta; B Verdoncq; P Orcel; C Roux
Journal:  Osteoporos Int       Date:  2005-07-20       Impact factor: 4.507

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.